Monograph
R03AC02 - Salbutamol |
Not porphyrinogenic |
NP |
Rationale
Rather low dose, in large parts excreted unmetabolized. No data pointing to CYP-interaction. Four references consider it safe.
Chemical description
Adrenergic beta-receptor stimulating agent used in asthma. Administered as salbutamol sulfate in micronized form in inhalation aerosol (2,5 - 5 mg/dose). No clinical data pointing to CYP-interaction. About 35% of the dose is excreted in unchanged form in urine. EPI-list: safe South African list: use French list: authorized. Kauppinen and Mustajoki. Prognosis of acute porphyria... Medicine 1992; 71: 1-13: tolerated (n=2)C. Andersson, patient reports: tolerated (n=1)
IPNet drug reports
Uneventful use reported in 21 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
